Search company, investor...


Founded Year



Seed | Alive

About Access

Access provides a financial application. The company aims to simplify investors' search for the right deals. It was founded in 2015 and is based in San Francisco, California.

Headquarters Location


San Francisco, California,

United States

Missing: Access's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Access's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Access

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Access is included in 3 Expert Collections, including Wealth Tech.


Wealth Tech

1,985 items

A category of financial technology that is digitizing & streamlining the delivery of wealth management. Included: Startups that offer technology-enabled tools for active and passive wealth management for retail investors and advisors.


Capital Markets Tech

822 items

Companies in the capital markets tech space are providing software and/or services for investment banks, hedge funds, investment managers, and so forth. Companies included use technology across the front, middle, and back-offices and streamline all pre- and post-trade operations.



7,941 items

US-based companies

Access Patents

Access has filed 547 patents.

The 3 most popular patent topics include:

  • Technical drawing
  • Graphical projections
  • Transiting exoplanets
patents chart

Application Date

Grant Date


Related Topics




Digestive system, Dietary supplements, Nutrition, Dosage forms, B vitamins


Application Date


Grant Date



Related Topics

Digestive system, Dietary supplements, Nutrition, Dosage forms, B vitamins



Latest Access News

VIDA Announces Series C Financing To Accelerate Access To AI-Powered Lung Imaging Analysis

Mar 13, 2020

VIDA Announces Series C Financing To Accelerate Access To AI-Powered Lung Imaging Analysis CORALVILLE, Iowa, March 12, 2020-- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, today announced an $11M initial close of its Series C financing. The investment was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures. Existing investors including Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, and The Angels' Forum also participated. VIDA will use the funds to address market deficits in the early assessment, monitoring, and treatment of lung disease by accelerating the commercialization of its leading LungPrint® solution suite and by expanding LungPrint's clinical portfolio. "We are driven to continuously raise the standard of care for patients with or at risk of lung disease. By equipping care teams with LungPrint, patient care and quality of life can be positively affected," said Susan A. Wood, Ph.D. and CEO for VIDA. "VIDA is endlessly thankful for the extensive support of the people, resources, and programs from the State of Iowa leading to this expansive funding. VIDA can now accelerate LungPrint's market access, further connecting its benefits to the many millions of patients with lung disease." "VIDA is an outstanding corporate citizen. The company's commitment of employing and training Iowa-based engineers and scientists not only contributes to our economic growth, but also reinforces our skilled, productive workforce. The State of Iowa is proud of VIDA's accomplishments, its worldwide recognition and to be a partner with them through robust economic development programs," said Iowa Governor Kim Reynolds. Lung disease impacts over 500 million people globally1, yet access to precise, personalized information for early detection and optimal treatment planning is not readily available. The development of AI (Artificial Intelligence) – driven lung analysis, like VIDA's LungPrint helps advance the standard of lung care by uniquely evaluating patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer. Using a chest CT scan, functional and other patient data as input, LungPrint provides care teams with a rich set of precise quantitative insights useful at all points in the care path, from detection through treatment. Expanded volume and complexity of information contributes increasingly to radiologist task overload and burnout. Chest CT scans are particularly tedious to interpret due to the extensive and complex search field. LungPrint improves radiology efficiency by AI-driven automation and visualization paradigms, and quality evaluations. VIDA is well positioned to address physician overload and burnout through a cadre of industry leading distribution partners, including Blackford, IBM Watson Health, Nuance Healthcare and TeraRecon, through the enhanced integration of LungPrint into the radiology workflow enabling diagnostic accuracy and workflow efficiency. “Pulmonology and radiology are severely underserved areas of healthcare – the need is expanding and the number of clinicians is limited. VIDA is in an optimal position to deliver innovation and increase access,” said Tracy Marshbanks, Managing Director and General Partner at First Analysis. “This investment will enable VIDA to meet the growing call for precise AI-driven lung analysis solutions that can help improve the quality of diagnosis and life for patients impacted by lung disease.” About VIDA VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer. VIDA's software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada and Australia. More at About First Analysis First Analysis is a leading venture capital investor, having invested more than $800 million over four decades. With our integrative research process, we aim to invest in the best, established rapid-growth companies in the targeted sectors where we are acknowledged experts and where our success benefits not only our investors, but also our broader society and environment. The integrative research process combines 1) dynamic investment research on thousands of publicly traded and privately held companies with 2) thousands of relationships among executives, investors, and other key participants in our focus areas, yielding a deep, comprehensive understanding of each sector's near-term and long-term potential. We help companies become profitable leaders in large markets, funding growth plans, working closely with management in areas including strategy, recruitment, sales and marketing, and corporate development, and typically investing $3-10 million as lead investor or as a syndicate partner who brings valuable perspective. About Blue Heron Capital Blue Heron Capital is an operationally focused private investment firm based in Richmond, Virginia. The firm invests in small-cap growth equity companies in the healthcare and tech-enabled business services sectors. Blue Heron supports portfolio companies with a team of industry experts, including C-level executives and successful entrepreneurs with decades of experience building and managing vibrant businesses. About UnityPoint Health Ventures Founded in 2019, UnityPoint Health Ventures makes direct investments in ideas and partners that provide an easier, more personal experience for patients and providers. As the venture capital arm of UnityPoint Health – one of the nation's most integrated health systems – the firm invests in opportunities that improve patient outcomes and reduce the cost of health care. In addition to strategic investing, UnityPoint Health Ventures provides dedicated resources to accelerate portfolio company traction within UnityPoint Health and beyond. Through relationships with more than 315 physician clinics, 21 regional and 19 community network hospitals in metropolitan and rural communities and home care services throughout its 9 regions, UnityPoint Health provides care throughout Iowa, western Illinois and southern Wisconsin. More at 1 World Health Organization (link)

Access Frequently Asked Questions (FAQ)

  • When was Access founded?

    Access was founded in 2015.

  • Where is Access's headquarters?

    Access's headquarters is located at Embarcadero, San Francisco.

  • What is Access's latest funding round?

    Access's latest funding round is Seed.

  • Who are the investors of Access?

    Investors of Access include Plug and Play Accelerator.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.